drugset / Trial / NCT03637543
Nivolumab in Patients With High-Risk Biochemically Recurrent Prostate Cancer
Phase 2
Active not recruiting
29 enrolled
Beth Israel Deaconess Medical Center
Bristol-Myers Squibb · collabDana-Farber Cancer Institute · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying an immune-based cancer drug as a possible treatment for prostate cancer. The drug involved in this study is: -Nivolumab
Timeline
- Start
- 2018-10-18
- Primary completion
- 2023-09-30
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |